
Loading, please wait...

Loading, please wait...

Diagnosing atypical plasma cell dyscrasias can be challenging when lesions develop outside the skeletal system. Although plasma cell neoplasms typically manifest as osteolytic lesions within bone marrow, extramedullary multiple myeloma presents as soft-tissue masses that can easily confound clinicians. Recently, an instructive case highlighted a 77-year-old male with a history of monoclonal gammopathy of undetermined significance who developed multiple bulky extraosseous soft-tissue masses. Because these lesions radiologically simulated lymphoproliferative disorders such as non-Hodgkin lymphoma, the clinical team required an extensive multi-tier evaluation. This diagnostic dilemma demonstrates why clinicians must maintain a high index of suspicion whenever patients with pre-existing plasma cell dyscrasias present with unusual mass lesions.
Monoclonal gammopathy of undetermined significance represents a premalignant condition that occasionally transforms into systemic plasma cell disorders. Consequently, routine surveillance remains standard practice to monitor for malignant transformation. In rare instances, clonal plasma cells acquire hematogenous dissemination capabilities and escape bone marrow microenvironment dependence. Therefore, malignant clones infiltrate soft tissues, organs, or lymphatic basins directly. This phenomenon leads to primary or secondary extraosseous tumors that behave aggressively. Moreover, the loss of adhesion molecules and altered chemokine receptor expression often drive this extramedullary migration. As a result, patients may present with rapid tumor growth and constitutional symptoms rather than classic hypercalcemia, renal dysfunction, anemia, or bone pain.
Cross-sectional imaging serves as an essential tool during the initial evaluation of occult oncologic processes. However, multimodality imaging can sometimes reveal overlapping characteristics between plasma cell neoplasms and lymphoproliferative diseases. On computed tomography, soft-tissue myelomatous masses frequently show homogeneous soft-tissue attenuation, well-circumscribed borders, and variable contrast enhancement. In addition, positron emission tomography using fluorodeoxyglucose demonstrates marked metabolic uptake in these lesions, indistinguishable from high-grade lymphomas. Furthermore, whole-body magnetic resonance imaging reveals intermediate signal intensity on T1-weighted sequences and hyperintensity on T2-weighted scans. Because these bulky masses can arise near nodal stations or abdominal organs, radiologists may initially suspect diffuse large B-cell lymphoma or systemic lymphadenopathy without immediate osseous involvement clues.
Differentiating soft-tissue plasma cell dyscrasias from systemic lymphomas requires careful synthesis of laboratory, metabolic, and anatomic findings. First, clinicians should evaluate serum and urine protein electrophoresis alongside serum free light chain ratios. While aggressive lymphomas occasionally produce secondary paraproteins, significant monoclonal protein elevation strongly points toward plasma cell pathology. Next, advanced functional imaging can clarify whether underlying diffuse marrow replacement exists. Nevertheless, imaging alone cannot reliably provide a definitive answer because both entities present with bulky adenopathy, extranodal disease, and intense metabolic avidity. Therefore, multidisciplinary tumor boards must integrate biochemical profiles and radiological patterns to guide timely interventional procedures.
Because imaging tests show substantial morphological overlap, tissue biopsy remains the gold standard for achieving an accurate diagnosis. Core needle biopsy or surgical excision yields adequate tissue architecture for comprehensive immunophenotyping. On microscopic examination, clonal plasma cells exhibit eccentric nuclei, clock-face chromatin, and abundant basophilic cytoplasm. Furthermore, immunohistochemical staining plays a decisive role in resolving diagnostic ambiguity. The malignant cells strongly express CD138, CD38, and cytoplasmic light chain restriction for either kappa or lambda. Conversely, they typically lack mature B-cell markers such as CD20, PAX5, and CD45, thereby ruling out classic B-cell lymphomas. Additionally, fluorescence in situ hybridization assists in identifying high-risk cytogenetic abnormalities that guide prognosis and therapy.
Establishing an exact diagnosis directly impacts therapeutic decision-making and survival outcomes. Because extraosseous disease represents a biologically aggressive myeloma phenotype, prompt initiation of systemic combination therapy is mandatory. Modern induction protocols typically incorporate proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and dexamethasone. Furthermore, eligible patients should undergo autologous stem cell transplantation to consolidate clinical remission. In localized symptomatic masses causing neural compromise or severe obstruction, clinicians often incorporate targeted radiation therapy. Regular disease surveillance requires repeat serum free light chain assays and serial fluorodeoxyglucose positron emission tomography scans to detect early recurrence and guide clinical adjustments.
Extramedullary disease involves plasma cell proliferation outside the skeletal marrow environment, affecting organs, lymph nodes, or soft tissues. It occurs in roughly six to eight percent of newly diagnosed myeloma patients and up to twenty percent during disease relapse. This manifestation typically reflects an aggressive biological phenotype requiring intensive systemic therapy.
Both entities present on imaging as bulky, homogeneous soft-tissue masses with variable contrast enhancement and intense metabolic uptake on positron emission tomography. Furthermore, myelomatous deposits frequently involve lymph node basins and retroperitoneal spaces without adjacent bone erosion, closely mimicking primary nodal and extranodal lymphomas.
A definitive diagnosis requires a core needle biopsy with immunohistochemical staining for CD138, CD38, and light chain restriction to differentiate plasma cells from lymphoma. Additionally, clinicians must correlate histopathology with serum free light chain assays, protein electrophoresis, and whole-body functional imaging.
Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A 77-year-old male with MGUS presented with bulky extraosseous soft-tissue masses mimicking lymphoma. Comprehensive imaging and histological correlation confirmed multifocal extraosseous multiple myeloma, emphasizing the importance of vigilant clinical workups in plasma cell dyscrasias.
2 months ago

A qualitative study investigates whether traditional bedside clinical examinations still mirror contemporary physician practice. Findings support retaining long cases while reforming short cases toward hypothesis-driven assessments.
Today

A pilot study evaluated WearDOXXN, a capillary microfluidic sweat patch, for noninvasive breast cancer monitoring by comparing sweat and serum CEA and PIP/GCDFP-15 levels.
Today

India faces a massive diabetes burden with over 89 million adults affected. Managing blood sugar in isolation fails to prevent severe cardiorenal complications. Clinicians must adopt an integrated metabolic ecosystem that prioritizes early detection, multifactorial risk assessment, and personalized therapies.
Today

The Gross Motor Function Classification System (GMFCS) stops its validated age bands at 18. Recent evidence emphasizes that evaluating adult cerebral palsy requires purpose-sensitive documentation combining adolescent ratings with dynamic profiles of mobility, fatigue, pain, and community participation.
Today

A breakthrough 3D-printed piezoelectric collagen hydrogel activated by ultrasound accelerates diabetic wound repair, demonstrating 98.5% wound closure, robust antibacterial action, and enhanced vascularization without toxic chemical crosslinkers.
Today